Oil prices hold sharp losses with focus on secondary India tariffs
BOULDER, CO - Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare company, announced today that its manufacturing facility and five of its products have been officially registered with the Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom. This development marks the company’s entry into the UK market, with products including a wound irrigation solution and scar management hydrogel.
Amy Trombly, CEO of Sonoma, stated that the registration with the MHRA allows the company to introduce its Microcyn-based products to the UK, highlighting the significance of this new market for their wound care and dermatology lines. The expansion comes as the company reports 13.51% revenue growth in the last twelve months. InvestingPro analysis suggests the stock is currently undervalued, with additional insights available through their comprehensive financial analysis tools.
Sonoma Pharmaceuticals specializes in stabilized hypochlorous acid (HOCl) products, which have been clinically proven to manage various conditions safely, including skin abrasions and lacerations, without harming healthy tissue. The company’s products are sold in 55 countries, and it actively pursues new distribution partnerships.
The company’s forward-looking statements indicate an anticipation of continued development and expansion, although they are subject to risks such as regulatory changes and market penetration challenges. Sonoma maintains its headquarters in Boulder, Colorado, with manufacturing in Guadalajara, Mexico, and European marketing based in Roermond, Netherlands.
This announcement is based on a press release statement from Sonoma Pharmaceuticals, Inc.
In other recent news, Sonoma Pharmaceuticals has entered into a significant Master Supply Agreement with WellSpring Pharmaceutical Corporation. This agreement, effective January 29, 2025, will allow Sonoma to distribute its Microcyn® technology-based products across major U.S. retailers. Although the financial terms of this agreement have not been disclosed, it represents a strategic move for the company to expand its market presence. The agreement has a two-year initial term with potential extensions, and details have been filed with the SEC.
Additionally, Sonoma Pharmaceuticals announced the completion of its annual equity grant to employees, including executive officers. Non-employee directors received 7,500 stock options each, with an exercise price of $2.68 per share, vesting over three years. Executive officers, including CEO Amy Trombly, CFO Jerry Dvonch, and COO Bruce Thornton, received 10,000 Restricted Stock Units (RSUs) each, which will vest in stages over two years. These equity grants are part of Sonoma’s strategy to retain key talent and align their interests with company goals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.